| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | George Kolios | |
| Dimitrios Damaskos | |||
| P2860 | cites work | A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease | Q22251291 |
| Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB | Q24290546 | ||
| Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice | Q24523182 | ||
| Effects of short chain fatty acids on gut morphology and function | Q24540325 | ||
| Diversity of the human intestinal microbial flora | Q24544241 | ||
| Phylogenetic identification and in situ detection of individual microbial cells without cultivation | Q24651527 | ||
| Interleukin-23 drives innate and T cell-mediated intestinal inflammation | Q24677051 | ||
| Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial | Q24685494 | ||
| Trichuris suis therapy in Crohn's disease | Q24685735 | ||
| Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine | Q24685766 | ||
| Dysbiosis in inflammatory bowel disease | Q24685931 | ||
| Lactobacillus GG in inducing and maintaining remission of Crohn's disease | Q24806098 | ||
| Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU) | Q28137606 | ||
| Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease | Q28143405 | ||
| Saccharomyces boulardii in maintenance treatment of Crohn's disease | Q28144634 | ||
| A pilot trial of Saccharomyces boulardii in ulcerative colitis | Q28184581 | ||
| Serological and DNA-based evaluation of Chlamydia pneumoniae infection in inflammatory bowel disease | Q37861895 | ||
| Metabolic and intestinal effects of short-chain fatty acids | Q37982824 | ||
| Intestinal flora in health and disease | Q39464842 | ||
| A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis | Q39774578 | ||
| Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair | Q40211588 | ||
| The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells | Q40231712 | ||
| Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways | Q40264330 | ||
| Functional modulation of enterocytes by gram-positive and gram-negative microorganisms | Q40580514 | ||
| Probiotic bacteria enhance murine and human intestinal epithelial barrier function | Q40783633 | ||
| Bifidobacterial species differentially affect expression of cell surface markers and cytokines of dendritic cells harvested from cord blood | Q41005375 | ||
| Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation. | Q41877251 | ||
| Wheat bran affects the site of fermentation of resistant starch and luminal indexes related to colon cancer risk: a study in pigs | Q42009307 | ||
| The postnatal development of gut lamina propria lymphocytes: number, proliferation, and T and B cell subsets in conventional and germ-free pigs | Q42121715 | ||
| Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. | Q42151699 | ||
| Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro | Q42282244 | ||
| Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. | Q42501287 | ||
| Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling | Q42704864 | ||
| Influence of mode of delivery on gut microbiota composition in seven year old children | Q43004871 | ||
| Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment | Q43005855 | ||
| Protein, and dietary fiber-rich new foodstuff from brewer's spent grain increased excretion of feces and jejunum mucosal protein content in rats | Q43331178 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production | Q43508047 | ||
| Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. | Q43618399 | ||
| Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis | Q43867015 | ||
| Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis | Q43979359 | ||
| Galacto-oligosaccharides stimulate the growth of bifidobacteria but fail to attenuate inflammation in experimental colitis in rats | Q44175493 | ||
| Variable response to probiotics in two models of experimental colitis in rats. | Q44231461 | ||
| Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis | Q44319566 | ||
| Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment | Q44364435 | ||
| Restoration of the integrity of rat caeco-colonic mucosa by resistant starch, but not by fructo-oligosaccharides, in dextran sulfate sodium-induced experimental colitis | Q44502404 | ||
| The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease | Q44541402 | ||
| Factors associated with ileal mucosal morphology and inflammation in patients with ileal pouch-anal anastomosis for ulcerative colitis | Q44647414 | ||
| Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial | Q28244734 | ||
| The first prebiotics in humans: human milk oligosaccharides | Q28268764 | ||
| CARD15/NOD2 mutations in Crohn's disease | Q28269971 | ||
| The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats | Q28283634 | ||
| Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics | Q28303404 | ||
| The First Prebiotics in Humans | Q29030288 | ||
| Unravelling the pathogenesis of inflammatory bowel disease | Q29547551 | ||
| Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach | Q29617547 | ||
| Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
| Assessment of Mucosal Inflammation and Circulation in Response to Probiotics in Patients Operated with Ileal Pouch Anal Anastomosis for Ulcerative Colitis | Q30927782 | ||
| Dietary fiber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis | Q32028300 | ||
| Crohn's disease and the NOD2 gene: a role for paneth cells | Q33187690 | ||
| Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease | Q33201542 | ||
| Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model | Q33256608 | ||
| Bifidobacterium infantis strains with and without a combination of oligofructose and inulin (OFI) attenuate inflammation in DSS-induced colitis in rats | Q33261861 | ||
| Dietary carbohydrate source influences molecular fingerprints of the rat faecal microbiota | Q33265107 | ||
| Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement | Q33265418 | ||
| Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein | Q33293246 | ||
| Fiber, inulin and oligofructose: similarities and differences | Q33681017 | ||
| Healthy gut microflora and allergy: factors influencing development of the microbiota | Q33730208 | ||
| Screening for bacillus isolates in the broiler gastrointestinal tract. | Q33785239 | ||
| Cytomegalovirus and inflammatory bowel disease: is there a link? | Q33866993 | ||
| Antibiotics and probiotics in treatment of inflammatory bowel disease. | Q33867934 | ||
| Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
| Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease | Q33885072 | ||
| Inflammatory bowel disease: the role of environmental factors | Q33980373 | ||
| Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease | Q34005313 | ||
| Oligofructose and long-chain inulin: influence on the gut microbial ecology of rats associated with a human faecal flora. | Q34086638 | ||
| Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. | Q34265403 | ||
| The NOD: a signaling module that regulates apoptosis and host defense against pathogens | Q34405567 | ||
| Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2 | Q34412531 | ||
| Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. | Q34415570 | ||
| Pre-, pro- and synbiotics. | Q34436976 | ||
| Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis | Q34445894 | ||
| Enteric defensins: antibiotic peptide components of intestinal host defense | Q36531732 | ||
| Influence of the gastrointestinal microbiota on development of the immune system in young animals. | Q36550079 | ||
| What immunologists should know about bacterial communities of the human bowel | Q36621022 | ||
| Therapeutic drug delivery by genetically modified Lactococcus lactis | Q36631447 | ||
| Homeostatic effects of TLR9 signaling in experimental colitis | Q36631507 | ||
| Recent understanding of IBD pathogenesis: implications for future therapies | Q36639759 | ||
| Bioecological control of inflammatory bowel disease. | Q36656873 | ||
| The use of Trichuris suis and other helminth therapies to treat Crohn's disease | Q36700626 | ||
| Intestinal helminths: a clue explaining the low incidence of inflammatory bowel diseases in Subsaharan Africa? Potential benefits and hazards of helminth therapy. | Q36753598 | ||
| Recent advances in basic and clinical aspects of inflammatory bowel disease: which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease? | Q36804314 | ||
| Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo | Q37084615 | ||
| Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression | Q37521881 | ||
| The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats | Q78753337 | ||
| Human milk is a source of lactic acid bacteria for the infant gut | Q79347590 | ||
| Germinated barley foodstuff suppresses dextran sulfate experimental colitis in rats: the role of mast cells | Q79488349 | ||
| Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4(+) CD45RB(high) T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation | Q79544250 | ||
| Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats | Q79756593 | ||
| Administration of Lactobacillus evokes coordinated changes in the intestinal expression profile of genes regulating energy homeostasis and immune phenotype in mice | Q80155949 | ||
| [Probiotics in chronic inflammatory bowel disease] | Q80330668 | ||
| Dietary supplementation of neutral and acidic oligosaccharides enhances Th1-dependent vaccination responses in mice | Q80511606 | ||
| The VSL# 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice | Q81550827 | ||
| Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells | Q81809212 | ||
| Goat milk oligosaccharides are anti-inflammatory in rats with hapten-induced colitis | Q82582145 | ||
| Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression | Q82789415 | ||
| Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis | Q83333118 | ||
| Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial | Q34510060 | ||
| Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans | Q34512635 | ||
| Role of the faecal stream in the maintenance of Crohn's colitis | Q34526492 | ||
| The expression of COX2 protein induced by Lactobacillus rhamnosus GG, endotoxin and lipoteichoic acid in T84 epithelial cells | Q34548513 | ||
| Probiotic therapy of intestinal inflammation and infections. | Q34554746 | ||
| Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases | Q34574528 | ||
| Psyllium as therapeutic and drug delivery agent | Q34576565 | ||
| Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. | Q35059717 | ||
| Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. | Q35594940 | ||
| Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC) | Q35595770 | ||
| Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. | Q35595783 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis | Q35596470 | ||
| Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease | Q35760252 | ||
| Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. | Q35760489 | ||
| Towards an understanding of the role of NOD2/CARD15 in the pathogenesis of Crohn's disease | Q35781073 | ||
| The role of bacterial infection in the pathogenesis of inflammatory bowel disease | Q35873621 | ||
| Human milk proteins: key components for the biological activity of human milk | Q35895609 | ||
| Antibiotics for inflammatory bowel disease: do they work? | Q36021421 | ||
| Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease | Q36035194 | ||
| Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators | Q36066805 | ||
| The role of epithelial Toll-like receptor expression in host defense and microbial tolerance. | Q36159073 | ||
| Interaction of mucosal microbiota with the innate immune system. | Q36161518 | ||
| Role of helminths in regulating mucosal inflammation | Q36164902 | ||
| Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease | Q36209704 | ||
| The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. | Q36220431 | ||
| Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice | Q36273531 | ||
| Mechanisms of disease: defensins in gastrointestinal diseases | Q36304262 | ||
| Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary. | Q36304837 | ||
| Modulation of the microbial ecology of the human colon by probiotics, prebiotics and synbiotics to enhance human health: an overview of enabling science and potential applications | Q36331925 | ||
| The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats | Q36364133 | ||
| Probiotics in the treatment of inflammatory bowel disease. | Q36457614 | ||
| Use of antibiotics in the treatment of inflammatory bowel disease | Q36521201 | ||
| Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. | Q44832516 | ||
| Breast milk and neonatal necrotising enterocolitis | Q44904712 | ||
| Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats | Q45104385 | ||
| Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis | Q45166043 | ||
| Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. | Q45244704 | ||
| Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis | Q45285907 | ||
| Oligosaccharides isolated from goat milk reduce intestinal inflammation in a rat model of dextran sodium sulfate-induced colitis | Q46866655 | ||
| Effects of quality of energy intake on growth and metabolic response of enterally fed low-birth-weight infants | Q47203769 | ||
| Human milk feedings and infection among very low birth weight infants | Q47282260 | ||
| DNA from probiotic bacteria modulates murine and human epithelial and immune function | Q47635337 | ||
| Effects of germinated barley foodstuff on dextran sulfate sodium-induced colitis in rats | Q48029355 | ||
| Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats | Q48035408 | ||
| Recovery of partial 16S rDNA sequences suggests the presence of Crenarchaeota in the human digestive ecosystem | Q48119465 | ||
| Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. | Q49073992 | ||
| Effects of mode of delivery and necrotising enterocolitis on the intestinal microflora in preterm infants | Q49215734 | ||
| Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. | Q51684873 | ||
| Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. | Q51720903 | ||
| Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial | Q51814797 | ||
| Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. | Q53622713 | ||
| Evaluation of probiotic treatment in a neonatal animal model. | Q54044323 | ||
| Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. | Q54486654 | ||
| Quantification of Bifidobacterium spp., Escherichia coli and Clostridium difficile in faecal samples of breast-fed and formula-fed infants by real-time PCR. | Q54492451 | ||
| Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. | Q54511436 | ||
| Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. | Q54572654 | ||
| Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. | Q54634996 | ||
| Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin | Q57241178 | ||
| Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations | Q57436454 | ||
| Specificities of the fecal microbiota in inflammatory bowel disease | Q58065017 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice | Q59120727 | ||
| Is Lactobacillus GG Helpful in Children With Crohn’s Disease? Results of a Preliminary, Open-Label Study | Q63285887 | ||
| Infection with Schistosoma mansoni alters Th1/Th2 cytokine responses to a non-parasite antigen | Q68055557 | ||
| Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission | Q68254807 | ||
| Lymphocyte subsets in jejunal and ileal Peyer's patches of normal and gnotobiotic minipigs | Q69740232 | ||
| Modulation of murine cytokine responses to mycobacterial antigens by helminth-induced T helper 2 cell responses | Q70504111 | ||
| Long-term ingestion of lactosucrose increases Bifidobacterium sp. in human fecal flora | Q70869297 | ||
| Effect of 4G-beta-D-galactosylsucrose (lactosucrose) on fecal microflora in patients with chronic inflammatory bowel disease | Q71535241 | ||
| Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group | Q71835035 | ||
| Effects of germinated barley foodstuff on microflora and short chain fatty acid production in dextran sulfate sodium-induced colitis in rats | Q73132962 | ||
| Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients | Q73157927 | ||
| Alteration of V beta usage and cytokine production of CD4+ TCR beta beta homodimer T cells by elimination of Bacteroides vulgatus prevents colitis in TCR alpha-chain-deficient mice | Q73163218 | ||
| Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats | Q73836774 | ||
| Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? | Q74126152 | ||
| Differences in Bifidobacterium flora composition in allergic and healthy infants | Q74181054 | ||
| Differential modulation of the immune response by breast- or formula-feeding of infants | Q74220268 | ||
| Combination therapy with Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides dramatically improved the intestinal function in a girl with short bowel syndrome: a novel synbiotics therapy for intestinal failure | Q74564631 | ||
| Preventive effects of Bifidobacterium- and Lactobacillus-fermented milk on the development of inflammatory bowel disease in senescence-accelerated mouse P1/Yit strain mice | Q77089238 | ||
| Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice | Q77659986 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| probiotics | Q1816730 | ||
| P304 | page(s) | 453-467 | |
| P577 | publication date | 2008-02-12 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. | |
| P478 | volume | 65 |
| Q37670529 | A Potential Role of Salmonella Infection in the Onset of Inflammatory Bowel Diseases |
| Q36536390 | A natural approach to treatment of inflammatory bowel disease |
| Q37332655 | A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. |
| Q92619703 | Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome |
| Q47159058 | Amelioration of the DSS-induced colitis in mice by pretreatment with 4,4'-diaponeurosporene-producing Bacillus subtilis |
| Q90307786 | Beyond Heat Stress: Intestinal Integrity Disruption and Mechanism-Based Intervention Strategies |
| Q57825805 | Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System |
| Q35558415 | Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome? |
| Q46251992 | Computational profiling of the gut-brain axis: microflora dysbiosis insights to neurological disorders |
| Q37445966 | Current status and challenges of cytokine pharmacology. |
| Q42796953 | Dietary Polydextrose Prevents Inflammatory Bowel Disease in Trinitrobenzenesulfonic Acid Model of Rat Colitis |
| Q33587942 | Early administration of probiotic Lactobacillus acidophilus and/or prebiotic inulin attenuates pathogen-mediated intestinal inflammation and Smad 7 cell signaling |
| Q53202355 | Effect of Lactobacillus casei on the Production of Pro-Inflammatory Markers in Streptozotocin-Induced Diabetic Rats. |
| Q33738228 | Effect of psyllium and gum Arabic biopolymers on the survival rate and storage stability in yogurt of Enterococcus duransIW3 encapsulated in alginate |
| Q94203482 | Erratum |
| Q64061620 | Fasting-Mimicking Diet Modulates Microbiota and Promotes Intestinal Regeneration to Reduce Inflammatory Bowel Disease Pathology |
| Q57169033 | Gut microbes as future therapeutics in treating inflammatory and infectious diseases: Lessons from recent findings |
| Q35605400 | Gut microbiota and sirtuins in obesity-related inflammation and bowel dysfunction |
| Q37372932 | Idiopathic inflammatory bowel disease in cats. Rational treatment selection |
| Q64912397 | Intestinal Microbiome, Small Intestinal Bacterial Overgrowth and Inflammatory Bowel Diseases - What are the Connections? |
| Q38863317 | Intestinal microbiome landscaping: insight in community assemblage and implications for microbial modulation strategies |
| Q35245299 | Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease |
| Q47139166 | Lactobacillus plantarum induces apoptosis in oral cancer KB cells through upregulation of PTEN and downregulation of MAPK signalling pathways. |
| Q37398741 | Managing gut health through nutrition |
| Q35683224 | Maternal Supplementation with Oligofructose (10%) during Pregnancy and Lactation Leads to Increased Pro-Inflammatory Status of the 21-D-Old Offspring. |
| Q34680857 | Microbial shift and periodontitis |
| Q94450998 | Microbiota-independent immunological effects of non-digestible oligosaccharides in the context of inflammatory bowel diseases |
| Q26750985 | Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients |
| Q46881285 | Mucosal intestinal alteration in experimental colitis correlates with nitric oxide production by peritoneal macrophages: effect of probiotics and prebiotics. |
| Q34987852 | Nondigestible oligosaccharides exert nonprebiotic effects on intestinal epithelial cells enhancing the immune response via activation of TLR4-NFκB. |
| Q90434725 | Nutraceuticals' Novel Formulations: The Good, the Bad, the Unknown and Patents Involved |
| Q40259746 | Oral Feeding of Probiotic Bifidobacterium infantis: Colonic Morphological Changes in Rat Model of TNBS-Induced Colitis |
| Q35550110 | Pea (Pisum sativum L.) seed albumin extracts show anti-inflammatory effect in the DSS model of mouse colitis |
| Q37681397 | Perspectives in the use of tannins as alternative to antimicrobial growth promoter factors in poultry |
| Q42454418 | Prebiotic oligosaccharides directly modulate proinflammatory cytokine production in monocytes via activation of TLR4. |
| Q55653409 | Preparation and characterization of alginate and psyllium beads containing Lactobacillus acidophilus. |
| Q35085664 | Probiotics as efficient immunopotentiators: translational role in cancer prevention |
| Q37361239 | Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials |
| Q35131051 | Probiotics, nuclear receptor signaling, and anti-inflammatory pathways |
| Q35590028 | Protective effect of aqueous extract of Oroxylum indicum Linn. (root bark) against DNBS-induced colitis in rats |
| Q54429291 | Regulation of the polymeric immunoglobulin receptor in intestinal epithelial cells by Enterobacteriaceae: implications for mucosal homeostasis. |
| Q34407175 | Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? |
| Q26784194 | Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases |
| Q90116200 | The effects of supplementation of Bacillus subtilis and Bacillus coagulans spores on the intestinal microflora and growth performance in rat |
| Q44587821 | The immunomodulatory properties of viable Lactobacillus salivarius ssp. salivarius CECT5713 are not restricted to the large intestine. |
| Q37771861 | The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models |
| Q37918323 | The intestinal microbiota and chronic disorders of the gut. |
| Q33919752 | The intestinal microbiota plays a role in Salmonella-induced colitis independent of pathogen colonization |
| Q57245618 | The use of probiotics in gastrointestinal diseases |
Search more.